Abcam, ab248972, Anti-CPM antibody [EPR8052] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CPM antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR8052,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248972 is the carrier-free version of
ab150405
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Carboxypeptidase M (CPM) is an enzyme that cleaves C-terminal basic residues from peptides and proteins. Also known as carboxypeptidase M1 CPM has a molecular weight of approximately 50 kDa. It is expressed on the surface of various cell types such as macrophages epithelial cells and specific tumor cells. CPM functions optimally at physiological pH and high levels of expression are seen in the lung placenta and kidney tissues. This broad expression pattern suggests that CPM plays significant roles in diverse physiological contexts.
Biological function summary
CPM is involved in peptide processing and degradation contributing to the regulation of hormonal and neurotransmitter peptides. As part of a larger proteolytic system CPM modifies the activity and half-life of bioactive peptides by removing terminal residues. Its activity influences the regulation of peptide signaling pathways. In such roles it resounds in processes like local inflammatory response and modulation of cell surface receptors. CPM’s enzymatic activity ensures the proper function of the physiological regulatory mechanisms where peptidase activity is required.
Pathways
CPM is instrumental in the kallikrein-kinin and complement pathways. In the kallikrein-kinin system CPM regulates kinin levels influencing blood pressure and inflammation. It also relates to the complement system interacting with components that participate in immune responses. CPM’s function closely links to other carboxypeptidases in these pathways enhancing its role in regulating peptide effects or degradation. Its enzymatic interactions can influence the outcomes of these pathways ensuring an adequate biological response.
CPM has associations with conditions like hypertension and chronic inflammation. Its influence on the kallikrein-kinin system corresponds to implications for blood pressure regulation connecting CPM to pathways affecting hypertension. In chronic inflammatory conditions CPM affects the local inflammatory response by modulating active peptide levels. Related proteins like carboxypeptidase N and other members of the metallocarboxypeptidase family augment this functional network highlighting CPM’s relevance in managing peptide-mediated pathological processes.